Recent Developments at Savara Inc.
Bragar Eagel & Squire, P.C. is reaching out to shareholders of Savara, Inc. to inform them about crucial legal proceedings related to the company. This news affects investors who hold securities in Savara, particularly those purchased between March 7, 2024, and May 23, 2025. It's essential for shareholders to be proactive in understanding their legal rights and options.
Overview of the Class Action Lawsuit
Key Events and Timeline
A class action lawsuit has been initiated against Savara Inc. (NASDAQ: SVRA), filed in the United States District Court for the Eastern District of Pennsylvania. The lawsuit impacts everyone who purchased Savara's securities during the established class period. A reminder that investors have until November 7, 2025, to apply to be appointed as lead plaintiff in this case.
Details of the Allegations
Core Claims
The allegations detailed in the lawsuit highlight significant concerns regarding the company's disclosure practices. Specifically, during the class period, Savara did not adequately inform investors about issues with the MOLBREEVI Biologics License Application (BLA). The complaint outlines that:
- There was insufficient information concerning the chemistry and manufacturing controls of the MOLBREEVI BLA.
- The failure to disclose this critical information led the FDA to decide against approving the BLA in its current form.
- This situation raised doubts about the likelihood of Savara meeting its projected submission deadlines for the BLA.
- Moreover, delayed regulatory approval may compel the company to seek additional capital.
Impact on Savara's Stock
Market Reactions
On May 27, 2025, Savara's share price dropped significantly following the announcement of an FDA refusal to file letter for the MOLBREEVI BLA. The company revealed that the FDA found the application insufficient for a substantive review, which led to a 31.69% decline in stock price, closing at $1.94 per share.
What Investors Should Do
If you are a long-time shareholder of Savara or have recently acquired shares and suffered a loss, it is crucial to take action. Shareholders are encouraged to reach out to legal experts for guidance on their rights and potential claims. Contact, Brandon Walker or Marion Passmore, directly at (212) 355-4648 for more insights into your situation.
About Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is a prominent national law firm committed to championing the rights of investors. With a dedicated approach to commercial and securities litigations in various state and federal courts, they offer a wealth of experience to those affected by corporate actions. For further information regarding their services or to discuss your rights, visit their website at www.bespc.com.
Frequently Asked Questions
What is the Savara class action lawsuit about?
The class action lawsuit claims that Savara failed to disclose critical information about the approval process for their MOLBREEVI BLA, potentially misleading investors.
Who can participate in the lawsuit?
Anyone who acquired Savara securities between March 7, 2024, and May 23, 2025, may be eligible to participate in the lawsuit.
When is the deadline to join the lawsuit?
The deadline for investors to apply to the Court to be appointed as lead plaintiff is November 7, 2025.
What should impacted investors do?
Investors feeling the effects of the allegations are encouraged to contact legal representatives to discuss their options and gather necessary information.
How can I get more information?
For more information on the lawsuit and your rights as an investor, please reach out to the firm at (212) 355-4648 or visit www.bespc.com.
